Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE A SALZBERG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1376528943
CMS profile
243136
Location
SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$41,911.39

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE A SALZBERG

NPI 1376528943 · CMS profile ID 243136

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SUWANEE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376528943?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376528943?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376528943?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 77 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1376528943?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $41,911.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $20.5412/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031300541 CMS
Celgene Corporation $2.9612/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015443345 CMS
Boston Scientific Corporation $13.2212/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022037793 CMS
Janssen Biotech, Inc. $8.1012/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206395 CMS
AbbVie Inc. $4.7612/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795839 CMS
AbbVie Inc. $6.4111/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795835 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.1911/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055581199 CMS
AbbVie Inc. $6.9711/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795829 CMS
Janssen Biotech, Inc. $6.7410/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206425 CMS
AbbVie Inc. $5.6310/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795823 CMS
Janssen Biotech, Inc. $4,050.0010/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054091 CMS
Janssen Biotech, Inc. $6,300.0010/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206365 CMS
Janssen Biotech, Inc. $60.1810/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054097 CMS
Janssen Biotech, Inc. $2,095.2610/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206375 CMS
Janssen Biotech, Inc. $180.3810/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206385 CMS
AbbVie Inc. $6.0210/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795817 CMS
Janssen Biotech, Inc. $1,350.0010/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206355 CMS
Janssen Biotech, Inc. $900.0010/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206345 CMS
AbbVie Inc. $6.1409/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795811 CMS
Janssen Biotech, Inc. $23.1609/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206405 CMS
AbbVie Inc. $10.7309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795807 CMS
Celgene Corporation $3.0409/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015443257 CMS
Celgene Corporation $3.9009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015443263 CMS
AbbVie Inc. $8.6308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795801 CMS
Janssen Biotech, Inc. $11.6708/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206415 CMS
AbbVie Inc. $30.5208/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795795 CMS
AbbVie Inc. $9.0408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795789 CMS
Janssen Biotech, Inc. $107.3007/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206327 CMS
Janssen Biotech, Inc. $13.6607/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206335 CMS
Celgene Corporation $7.7807/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015443203 CMS
AbbVie Inc. $6.1207/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795783 CMS
Janssen Biotech, Inc. $4,050.0007/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206277 CMS
Janssen Biotech, Inc. $128.2107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206289 CMS
Janssen Biotech, Inc. $329.6807/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206299 CMS
Janssen Biotech, Inc. $1,783.3807/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206307 CMS
Janssen Biotech, Inc. $244.9807/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206317 CMS
Janssen Scientific Affairs, LLC $6.8407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988522325 CMS
Celgene Corporation $116.5407/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015443221 CMS
AbbVie Inc. $9.2706/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998795779 CMS
Janssen Biotech, Inc. $55.8606/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206536 CMS
Janssen Biotech, Inc. $31.0006/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206545 CMS
Janssen Biotech, Inc. $14.8606/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206555 CMS
Janssen Biotech, Inc. $6,300.0006/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206465 CMS
Janssen Biotech, Inc. $4,050.0006/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206485 CMS
Janssen Biotech, Inc. $396.3206/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206475 CMS
Janssen Biotech, Inc. $91.2506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206495 CMS
Janssen Biotech, Inc. $221.2206/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206505 CMS
Janssen Biotech, Inc. $897.7506/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206515 CMS
Janssen Biotech, Inc. $361.8906/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206527 CMS
Janssen Biotech, Inc. $17.6206/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988206639 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $87,088.72 183
PY2020 $25,152.08 58
PY2021 $17,526.51 124
PY2022 $46,620.72 107
PY2023 $41,911.39 77
PY2024 $16,306.24 46
PY2025 $40,647.25 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $35,777.10 3
PY2023 Principal investigator $4,640.61 4
PY2022 Principal investigator $52,325.70 12
PY2021 Principal investigator $131,307.67 47
PY2020 Recipient $7,898.24 3
PY2020 Principal investigator $335,230.92 133
PY2019 Recipient $12,040.75 4
PY2019 Principal investigator $611,218.71 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $42.00 12/16/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies No dispute reported 06/30/2026 792487445
Principal investigator 1 ABBVIE INC. $2,680.80 12/16/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792487705
Principal investigator 1 Eli Lilly and Company $1,226.40 12/15/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 819452885
Principal investigator 1 ABBVIE INC. $1,129.25 11/17/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792483091
Principal investigator 1 ABBVIE INC. $1,150.80 11/17/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792483361
Principal investigator 1 Gilead Sciences, Inc. $1,353.00 11/17/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 803530977
Principal investigator 1 Janssen Research & Development, LLC $4,470.00 11/08/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists
Phase 3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 787621965
Principal investigator 1 Janssen Research & Development, LLC $3,895.00 11/03/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Long term Exposure Registry of Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 787621999
Principal investigator 1 ABBVIE INC. $6,790.80 10/14/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792479723
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $910.00 10/01/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) No dispute reported 06/30/2026 816763003
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $192.15 09/20/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Associates
Phase 2 UC Primary represents Induction No dispute reported 06/30/2026 819891635
Principal investigator 1 Genentech, Inc. $1,080.90 09/14/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 835938547
Principal investigator 1 ABBVIE INC. $8,640.75 08/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792473087
Principal investigator 1 Gilead Sciences, Inc. $1,671.00 08/23/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 803530975
Principal investigator 1 ABBVIE INC. $4,347.60 07/29/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792470807
Principal investigator 1 ABBVIE INC. $6,103.25 06/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792464819
Principal investigator 1 ABBVIE INC. $1,720.50 06/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies No dispute reported 06/30/2026 792465099
Principal investigator 1 ABBVIE INC. $5,580.20 06/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792465757
Principal investigator 1 Eli Lilly and Company $70.25 06/25/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 819451557
Principal investigator 1 ABBVIE INC. $1,513.00 06/08/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792462515
Principal investigator 1 ABBVIE INC. $5,615.82 06/08/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792462575
Principal investigator 1 ABBVIE INC. $1,759.40 06/08/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792462671
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/03/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302) No dispute reported 06/30/2026 816729859
Principal investigator 1 Gilead Sciences, Inc. $1,353.00 05/19/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 803530973
Principal investigator 1 ABBVIE INC. $5,754.00 05/10/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792456381
Principal investigator 1 ABBVIE INC. $87.50 05/05/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792453767
Principal investigator 1 ABBVIE INC. $4,771.62 05/05/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792453885
Principal investigator 1 ABBVIE INC. $1,547.25 04/29/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792449271
Principal investigator 1 Janssen Research & Development, LLC $779.00 04/29/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Long term Exposure Registry of Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 787621983
Principal investigator 1 Gilead Sciences, Inc. $954.00 04/26/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 803530971
Principal investigator 1 Janssen Research & Development, LLC $991.00 04/22/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 787622015
Principal investigator 1 Janssen Research & Development, LLC $8,557.00 04/22/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, PC
Phase 3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 787622033
Principal investigator 1 ABBVIE INC. $4,378.80 04/07/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792443048
Principal investigator 1 ABBVIE INC. $1,193.00 03/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792437377
Principal investigator 1 ABBVIE INC. $1,144.06 03/30/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792438313
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/29/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787621911
Principal investigator 1 Janssen Research & Development, LLC $1,991.00 03/25/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 787621929
Principal investigator 1 ABBVIE INC. $1,915.82 03/03/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792431721
Principal investigator 1 ABBVIE INC. $2,699.00 03/02/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792428301
Principal investigator 1 Gilead Sciences, Inc. $2,015.00 02/17/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY ASSOCIATES
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 803530969
Principal investigator 1 Janssen Research & Development, LLC $5,250.00 02/05/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787621891
Principal investigator 1 Janssen Research & Development, LLC $5,760.00 02/05/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALIST S PC
A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 787621947
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $268.75 02/02/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECI
EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE No dispute reported 06/30/2026 816686932
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $268.75 02/02/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECI
EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE No dispute reported 06/30/2026 816686941
Principal investigator 1 ABBVIE INC. $9,475.50 01/28/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy No dispute reported 06/30/2026 792414735
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,745.05 01/11/2021 Non-covered Recipient Entity
Atlanta Gastroenterology Specialists, Pc
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 819891641
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $365.70 01/07/2021 Non-covered Recipient Entity
ATLANTA GASTROENTEROLOGY SPECIALISTS PC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A VEDOLIZUMAB IV REFERENCE ARM, TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 816678723